# Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

> **NCT05228743** · NA · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **PROCEDURE:** Comparing Hyperthermic Intraperitoneal Chemotherapy
- **DRUG:** Paclitaxel
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT05228743
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228743, "Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05228743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*